CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024
Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its plan to release second quarter 2024 financial results on August 14, 2024, before the market opens. The company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day.
Investors and interested parties can access the conference call through the following options:
- Domestic: 1-877-270-2148
- International: 1-412-902-6510
- Webcast: Available via provided link
This announcement indicates CorMedix's commitment to transparency and shareholder communication, providing an opportunity for stakeholders to gain insights into the company's financial performance and recent developments.
Positive
- Timely disclosure of quarterly financial results
- Hosting a corporate update conference call for investors
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CRMD declined 2.60%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 14, 2024, and will host a corporate update conference call at 8:30am Eastern Time.
Wednesday, August 14th @ 8:30am ET
| Domestic: | 1-877-270-2148 |
| International: | 1-412-902-6510 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will CorMedix (CRMD) report its Q2 2024 financial results?
What time is CorMedix's (CRMD) Q2 2024 earnings call scheduled for?
How can investors access CorMedix's (CRMD) Q2 2024 earnings call?
What is CorMedix's (CRMD) main business focus?
